| 2024.04.10 | FDA has granted Fast Track Designation to Tamibarotene for the treatment of Newly Diagnosed Unfit AML. |
|---|---|
| 2023.01.27 | FDA has granted Fast Track Designation to Tamibarotene for the treatment of higher risk MDS. |
| 2022.08.04 | EMA committee issued Positive Opinion to TM-411 for MDS on Orphan Drug Designation. |
| 2022.07.11 | Approval of use patent for TM-411 as a cancer stem cell proliferation inhibitor by European Patent Office. |
